Labs at NuvOx Pharma, Innovation in Oxygen Therapy
Although, NVX-108 is said to address a number of medical conditions where low oxygen is a problem, the present NCI award allows NuvOx to focus on treating cancer.
Labs at NuvOx Pharma, Innovation in Oxygen Therapy
“We are so pleased that this funding will fully support our team on a project in which we will be able to optimize and preliminarily test our product, NVX-108, against cancer.”
Labs at NuvOx Pharma, Innovation in Oxygen Therapy
NVX-108 is an oil-in-water emulsion (a stable suspension of small liquid particles evenly dispersed within a second liquid) of an oxygen carrier...
Labs at NuvOx Pharma, Innovation in Oxygen Therapy
NuvOx Pharma's NVX-108, a treatment to make cancer tumors more susceptible to radiation therapy.
Labs at NuvOx Pharma, Innovation in Oxygen Therapy
NuvOx Pharma llc., local Tucson, Arizona, Biotech Company is Awarded Grant Funds to Develop a Cancer Treatment for Solid Malignant Tumors with Low Oxygen Content.
Labs at NuvOx Pharma, Innovation in Oxygen Therapy
NuvOx Pharma's technology uses a compound known as dodecafluoropentane, originally developed as an imaging contrast agent, to carry oxygen to tumor cells.
Labs at NuvOx Pharma, Innovation in Oxygen Therapy
The presence of oxygen in tumors is necessary for radiation treatments to inflict harm on cancerous cells.
Labs at NuvOx Pharma, Innovation in Oxygen Therapy
Tucson Biotech Gets a Nod from the National Cancer Institute to Develop a Treatment for Solid Malignant Tumors.

NuvOx Pharma is a biotechnology company based in Tucson, Arizona with a novel patent portfolio allowing it to develop an innovative platform of dodecafluoropentane (DDFP)-based oxygen therapeutics to treat a host of human conditions. Founded in 2008, NuvOx Pharma has demonstrated therapeutic feasibility in radiation-resistant cancer, hemorrhagic shock, traumatic brain injury, myocardial infarction, retinopathy and stroke. Due to inherent structure of DDFP, a very stable and relative lack of inter-molecular attractive forces, this perfluorocarbon is known to carry large payloads of oxygen in the bloodstream. The main advantage to using DDFP is that it is a liquid at room temperature, but expands to the gas state in the body. Therefore, upon intravenous injection the transition of DDFP from a liquid to a gas in the bloodstream allows for ~600 times increased oxygen transport compared to Hemoglobin.